Cogstate (ASX:CGS) Shares Slip Today: What Are Investors Watching in the 1Q27 Contract Update?

Sonal Goyal

06 November 2026 06:09 PM AEDT

Cogstate (ASX:CGS) Shares Slip Today: What Are Investors Watching in the 1Q27 Contract Update?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Cogstate (ASX:CGS) traded at A$3.29 during the 6 November 2026 session, down 2.66%.
Net sales contracts executed in 1Q27 totalled US$25.1 million, per its 12 October 2026 update.
The company said it is combining CNS endpoint expertise with a growing channel partner ecosystem.

Cogstate (ASX:CGS) shares were quoted at A$3.29 during the 6 November 2026 trading session, down 2.66%. The S&P/ASX 200 Health Care index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. The session move is not linked to the 12 October 2026 Business update. Cogstate provides digital cognitive assessments and clinical trial endpoint data to pharmaceutical sponsors.

Latest Developments

1Q27 Business Update (released 12 October 2026)

Cogstate reported net sales contracts executed in the quarter ended 30 September 2026 of US$25.1 million. The company described the result as continued execution of its strategy to combine scientific Leadership in CNS endpoint quality with a channel partner ecosystem, so sponsors can use its expertise while working with their preferred clinical technology providers. The update included a table of recent quarterly net sales contracts for context.

About the Company

Cogstate is an ASX-listed company that provides cognitive assessment technology and data quality services for clinical trials.

Business Overview

Cogstate sells digital cognitive assessments and endpoint data services to pharmaceutical and clinical research sponsors. Its results are driven by net sales contracts, which are reported quarterly.

Sector Context

The S&P/ASX 200 Health Care Index (XHJ) eased 0.20% to 35,258.30 during the same session, while the S&P/ASX 200 was down 0.49% at 9,020.80. Clinical trial service providers depend on pharmaceutical and biotech spending, and contract timing can vary widely from quarter to quarter.

Risks to Watch

Net sales contracts can be lumpy, and the shift toward channel partners changes how Revenue is generated. Biotech funding conditions affect sponsor spending.

Catalysts on Watch

Investors may follow the 2Q27 business update, the performance of channel partnerships and any large contract announcements.

Final Takeaways

Cogstate (ASX:CGS) traded lower on 6 November 2026 in a session where the health care index eased. Its 1Q27 update, dated 12 October 2026, reported US$25.1 million of net sales contracts.

FAQs

Q: What was the CGS share price on 6 November 2026?

A: Cogstate shares were quoted at A$3.29 during the trading session, down 2.66%.

Q: What were 1Q27 net sales contracts?

A: US$25.1 million.

Q: What is Cogstate's business?

A: Digital cognitive assessments and endpoint data for clinical trials.

Q: What strategy did the company describe?

A: Combining CNS endpoint expertise with a channel partner ecosystem.

Q: Is the session move linked to the update?

A: No. The update was dated 12 October 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.